EvolusEOLS -0.21%71 Forward Dividend Yield % is 0.00% as of Jun. 27, 2026. GuruFocus rates EOLS with a GF Score™ of 71/100 and a GF Value™ of $13.60 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 504 Drug Manufacturers companies, Evolus ranks worse than 198412.5% on this metric.
As of today (2026-06-27), the Forward Annual Dividend Yield of Evolus is 0.00%.
As of today (2026-06-27), the Trailing Annual Dividend Yield of Evolus is 0.00%.
EOLS's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.08 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
EOLS vs EBS, ELTP, AQST: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evolus's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Evolus's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Evolus (EOLS) has a Forward Dividend Yield % of 0.00% as of Jun. 27, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Evolus and its competitors. According to the industry distribution chart, Evolus ranks #999999 out of 504 companies in the Drug Manufacturers industry.
Is Evolus' Forward Dividend Yield % too high?
Evolus' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Evolus ranks #999999 out of 504 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evolus has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' Forward Dividend Yield % compare to EBS and ELTP?
According to the Drug Manufacturers industry distribution chart, Evolus ranks #999999 out of 504 companies for Forward Dividend Yield %. This places Evolus in the lower half of its industry. The industry median Forward Dividend Yield % is 2.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.08, based on 504 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Evolus and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolus's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.60, compared to a current price of $7.13 — trading 47.6% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Evolus' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Evolus (EOLS), the current Forward Dividend Yield % is 0.00% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolus (EOLS) Overvalued in 2026?
Based on GuruFocus' analysis, Evolus stock appears to be undervalued.
The current stock price of $7.13 is trading 47.6% below its estimated GF Value™ of $13.60.
GuruFocus considers Evolus to be Possible Value Trap.
Key valuation signals for EOLS:
Forward Dividend Yield %: 0.00%
GF Value™: $13.60 vs. price of $7.13 (47.6% below fair value)
No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
71GF Score
Get the complete analysis for EOLS
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EOLS has been successfully added to your 